[1. Gabrys D, Wesolowska I, Suwinski R. The evaluation of 3DRT and IMRT techniques in postoperative radiotherapy for thyroid medullary carcinoma. Rep Pract Oncol Radiother 2008; 13: 126-9.10.1016/S1507-1367(10)60002-8]Search in Google Scholar
[2. Miften MM, Das SK, Su M, Marks LB. A dose-volume-based tool for evaluating and ranking IMRT treatment plans. J Appl Clin Med Phys 2004; 5: 1-14.10.1120/jacmp.v5i4.1981]Search in Google Scholar
[3. Trojanowska A. Squamous cell carcinoma of the head and neck-The role of diffusion and perfusion imaging in tumor recurrence and follow-up. Rep Pract Oncol Radiother 2011; 16: 203-8.10.1016/j.rpor.2011.06.006]Search in Google Scholar
[4. Buettner F, Miah AB, Gulliford SL, Hall E, Harrington KJ, Webb S, et al. Novel approaches to improve the therapeutic index of head and neck radiotherapy: An analysis of data from the PARSPORT randomised phase III trial. Radiother Oncol 2012; 103: 82-7.10.1016/j.radonc.2012.02.006]Search in Google Scholar
[5. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. PARSPORT trial management group. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011; 12: 127-36.10.1016/S1470-2045(10)70290-4]Search in Google Scholar
[6. Binhu J, Supe S, Pawar Y. Intensity modulated radiotherapy (IMRT) the white, black and grey: a clinical perspective. Rep Pract Oncol Radiother 2009; 14: 95-103.10.1016/S1507-1367(10)60101-0]Search in Google Scholar
[7. Rosenthal DI, Chambers MS, Fuller CD, Rebueno NCS, Garcia J, Kies MS, et al. Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2008; 72: 747-55.10.1016/j.ijrobp.2008.01.01218455324]Search in Google Scholar
[8. Sas-Korczyńska B, Śladowska A, Rozwadowska-Bogusz B, Dyczek S, Lesiak J, Kokoszka A, et al. Comparison between intensity modulated radiotherapy (IMRT) and 3D tangential beams technique used in patients with early-stage breast cancer who received breast-conserving therapy. Rep Pract Oncol Radiother 2010; 15: 79-86.10.1016/j.rpor.2010.06.002386316224376929]Search in Google Scholar
[9. Lee N, Puri DR, Blanco AI, Chao KSC. Intensity modulated radiation therapy in head and neck cancers: An update. Head Neck 2007; 29: 387-400.10.1002/hed.2033216358297]Search in Google Scholar
[10. Bhide SA, Nutting CM. Advances in radiotherapy for head and neck cancer. Oral Oncology 2010; 46: 439-41.10.1016/j.oraloncology.2010.03.00520409746]Search in Google Scholar
[11. Clark CH, Hansen VN, Chantler H, Edwards C, James HV, Webster G, et al. Dosimetry audit for a multi-centre IMRT head and neck trial. Radiother Oncol 2009; 93: 102-8.10.1016/j.radonc.2009.04.025]Search in Google Scholar
[12. Tribius S, Bergelt C. Intensity-modulated radiotherapy versus conventional and 3D conformal radiotherapy in patients with head and neck cancer: Is there a worthwhile quality of life gain? Cancer Treat Rev 2011; 37: 511-9.]Search in Google Scholar
[13. Piotrowski T, Martenka P, De Patoul N, Jodda A, Coevoet M, Malicki J, et al. The new two-component conformity index formula (TCCI) and dose-volume comparisons of the pituitary gland and tonsil cancer IMRT plans using a linear accelerator and helical tomotherapy. Rep Pract Oncol Radiother 2009; 14: 133-45.10.1016/S1507-1367(10)60028-4]Search in Google Scholar
[14. Grzadziel A, Grosu A, Kneschaurek P. Three-dimensional conformal versus intensity-modulated radiotherapy dose planning in stereotactic radiotherapy: Application of standard quality parameters for plan evaluation. Int J Rad Oncol Biol Phys 2006; 66: S87-94.10.1016/j.ijrobp.2006.01.056]Search in Google Scholar
[15. Pesznyak C, Polgar I, Weisz C, Kiraly R, Zarand P. Verification of quality parameters for portal image in radiotherapy. Radiol Oncol 2011; 45: 66-74.10.2478/v10019-010-0052-6]Search in Google Scholar
[16. Bailey DW, Kumaraswamy L, Podgorsak MB. A Fully electronic intensitymodulated radiation therapy quality assurance (IMRT QA) process implemented in a network comprised of independent treatment planning, record and verify, and delivery systems. Radiol Oncol 2010; 44: 124-30.10.2478/v10019-010-0017-9]Search in Google Scholar
[17. Mendenhall W, Mancuso A. Radiotherapy for head and neck cancer - is the “next level” down? Int J Radiat Oncol Biol Phys 2009; 73: 645-6.]Search in Google Scholar
[18. Kry SF, Salehpour M, Followill DS, Stovall M, Kuban DA, Rosen II. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2005; 62: 1195-203.10.1016/j.ijrobp.2005.03.053]Search in Google Scholar
[19. Howell RM, Scarboro SB, Kry SF, Yaldo DZ. Accuracy of out-ofi-field dose calculations by a commercial treatment planning system. Phys Med Biol 2010; 55: 6999-7008.10.1088/0031-9155/55/23/S03]Search in Google Scholar
[20. Prescribing, Recording, and Reporting Photon Beam Therapy (Report 50), ICRU Report No. 50; 1993.]Search in Google Scholar
[21. Prescribing, Recording and Reporting Photon Beam Therapy (Report 62), (Supplement to ICRU Report 50), ICRU Report 62; 1999.]Search in Google Scholar
[22. Reference Data for the Validation of Doses from Cosmic-Radiation Exposure of Aircraft Crew (ICRU 84), ICRU Report 84. Journal of the ICRU 2012; 10(2).]Search in Google Scholar
[23. Hall E, Wuu C. Radiation-induced second cancers: the impact of 3D-CRT and IMRT1. Int J Radiat Oncol Biol Phys 2003; 56: 83-8.10.1016/S0360-3016(03)00073-7]Search in Google Scholar
[24. Dorr W, Stewart FA. Retreatment tolerance of normal Tissues. In: Basic Clinical Radiobiology. Joiner M and van der Kogel A, editors. 4th Edition. London: Hodder Arnold; 2009. p. 259-90.10.1201/b13224-20]Search in Google Scholar
[25. Marks LB, Yorke ED, Jackson A, Ten Haken RT, Comstine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Rad Oncol Biol Phys 2010; 76(3 Suppl): S10-9.10.1016/j.ijrobp.2009.07.1754404154220171502]Search in Google Scholar
[26. Kupchak C, Battista J, Van Dyk J. Experience-driven dose-volume histogram maps of NTCP risk as an aid for radiation treatment plan selection and optimization. Med Phys 2008; 35: 333-43.10.1118/1.2815943]Search in Google Scholar
[27. Mendenhall WM, Amdur RJ, Palta JR. Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J Clin Oncol 2006; 24: 2618 -23.10.1200/JCO.2005.04.7225]Search in Google Scholar
[28. Chen AM, Hall WH, Li B-Q, Guiou M, Wright C, Mathai M, et al. Intensitymodulated radiotherapy increases dose to the brachial plexus compared with conventional radiotherapy for head and neck cancer. Br J Radiol 2011; 84: 58-63.10.1259/bjr/62332495]Search in Google Scholar
[29. Longobardi B, De Martin E, Fiorino C, Delloca I, Broggi S, Cattaneo GM, et al. Comparing 3DCRT and inversely optimized IMRT planning for head and neck cancer: Equivalence between step-and-shoot and sliding window techniques. Radiother Oncol 2005; 77: 148-56.10.1016/j.radonc.2005.09.011]Search in Google Scholar
[30. Winiecki J, Zurawski Z, Drzewiecka B, Slosarek K. Anatomy-corresponding method of IMRT verification. Rep Pract Oncol Radiother 2011; 16: 1-9.10.1016/j.rpor.2010.11.001]Search in Google Scholar
[31. Malicki J., Litoborski M, Kierzkowski J, Kosicka G. How the implementation of an in-vivo dosimetry protocol improved the dose delivery accuracy in head and neck radiotherapy. Neoplasma 2004; 51: 155-8.]Search in Google Scholar
[32. Knöös T, Kristensen I, Nilsson P. Volumetric and dosimetric evaluation of radiation treatment plans: radiation conformity index. Int J Radiat Oncol Biol Phys 1998; 42:1169-76.10.1016/S0360-3016(98)00239-9]Search in Google Scholar
[33. Clark CH, Miles EA, Urbano MTG, Bhide SA, Bidmead AM, Harrington KJ, et al. Pre-trial quality assurance processes for an intensity-modulated radiation therapy (IMRT) trial: PARSPORT, a UK multicentre Phase III trial comparing conventional radiotherapy and parotid-sparing IMRT for locally advanced head and neck cancer. Br J Radiol 2009; 82: 585-94.10.1259/bjr/3196650519332518]Search in Google Scholar
[34. Guerrero Urbano MT, Clark CH, Kong C, Miles E, Dearnaley DP, Harrington KJ, et al. Target volume definition for head and neck intensity modulated radiotherapy: Pre-clinical evaluation of PARSPORT trial guidelines. Clin Oncol 2007; 19: 604-13.10.1016/j.clon.2007.07.00117706404]Search in Google Scholar
[35. Gizynska M, Zawadzka A. IMRT versus 3D-CRT for thyroid cancer. Pol J Med Phys Eng 2008; 14: 151-62.10.2478/v10013-008-0013-1]Search in Google Scholar
[36. Malicki J. The importance of accurate treatment planning, delivery, and dose verification. Rep Pract Oncol Radiother 2012; 17: 63-5.10.1016/j.rpor.2012.02.001386326124377001]Search in Google Scholar